Search research articles
Contact Us
Filters
Showing results (511-520 of 594) with videos related to
Page
of 60
Sort By:
Journal of the National Cancer Institute
|
February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials
Eric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2022
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC
Pedro Rocha, Jiexin Zhang, Raquel Laza-Briviesca, et al.
Cancer Research
|
December 4, 2012
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma
Pierre Saintigny, Erminia Massarelli, Steven Lin, et al.
Nature Communications
|
August 8, 2018
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
Jingying Nong, Yuhua Gong, Yanfang Guan, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
February 22, 2022
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer
Boris Sepesi, Nicolas Zhou, William N William, et al.
Science Translational Medicine
|
November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
Monique B Nilsson, Huiying Sun, Lixia Diao, et al.
JTO Clinical and Research Reports
|
August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Journal of the National Cancer Institute
|
January 17, 2012
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome
Nathan T Ihle, Lauren A Byers, Edward S Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC
Xiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Page
of 60
Search research articles
Search
Showing results (511-520 of 594) with videos related to
Sort By:
Page
of 60
Journal of the National Cancer Institute
|
February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials
Eric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2022
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC
Pedro Rocha, Jiexin Zhang, Raquel Laza-Briviesca, et al.
Cancer Research
|
December 4, 2012
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma
Pierre Saintigny, Erminia Massarelli, Steven Lin, et al.
Nature Communications
|
August 8, 2018
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
Jingying Nong, Yuhua Gong, Yanfang Guan, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
February 22, 2022
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer
Boris Sepesi, Nicolas Zhou, William N William, et al.
Science Translational Medicine
|
November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
Monique B Nilsson, Huiying Sun, Lixia Diao, et al.
JTO Clinical and Research Reports
|
August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Journal of the National Cancer Institute
|
January 17, 2012
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome
Nathan T Ihle, Lauren A Byers, Edward S Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC
Xiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Page
of 60